Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chou AJ et al. - In a study to examine the addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) to chemotherapy for pts with metastatic osteosarcoma (OS), it was found that when the metastatic cohort was considered in isolation, addition of liposomal MTP-PE to chemotherapy did not achieve a statistically significant improvement in outcome. But the pattern of outcome is similar to the pattern in nonmetastatic pts.

Methods

Results

Today in Pharmacology/Therapy...keeping you current

Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address